You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 265 No. 8, February 27, 1991 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contributions
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Lovastatin Efficacy in Reducing Low-Density Lipoprotein Cholesterol Levels on High- vs Low-Fat Diets

Margaret M. Cobb, MD, PhD; Howard S. Teitelbaum, DO, PhD; Jan L. Breslow, MD

JAMA. 1991;265(8):997-1001.


Abstract

The effectiveness of lovastatin was compared with both a high-fat vs low-fat diet. Hypercholesterolemic subjects were studied under metabolic ward conditions for diet periods of 3 weeks while receiving lovastatin (40 mg/d) or placebo. Multiple lipoprotein levels were measured during the final week of each diet period. Nineteen subjects completed the study on the high-fat (43% of kilojoules) diet and 16 on the low-fat (25% of kilojoules) diet. Lovastatin reduced total cholesterol by 23% and low-density lipoprotein cholesterol by 30%, compared with placebo on both diets, with no significant diet-drug interaction. High-density lipoprotein cholesterol was raised by 7% to 8% on the diet regimens. Addition of lovastatin to the low-fat diet permitted 80% of subjects on this diet, but less than 50% of those on the high-fat diet, to achieve current guidelines. Although lovastatin produces a comparable percentage reduction in lipoprotein profiles on either diet, the accompanying low-fat diet remains advisable for additional reduction of low-density lipoprotein cholesterol levels to specified goals.

(JAMA. 1991;265:997-1001)



Author Affiliations

From the Laboratory of Biochemical Genetics and Metabolism, The Rockfeller University, New York, NY (Drs Cobb and Breslow), and Department of Community Health Science, Michigan State University, East Lansing (Dr Teitelbaum).


Footnotes

Reprint requests to 1735 York Ave, New York, NY 10128 (Dr Cobb).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Why some patients respond poorly to statins and how this might be remedied
Thompson et al.
Eur Heart J 2002;23:200-206.
FULL TEXT  

Forecasting Patient Outcomes in the Management of Hyperlipidemia
Brier et al.
Arch Intern Med 1999;159:569-575.
ABSTRACT | FULL TEXT  

Efficacy of Low-Dose Cholesterol-Lowering Drug Therapy in Men With Moderate Hypercholesterolemia
Denke and Grundy
Arch Intern Med 1995;155:393-399.
ABSTRACT  

Individual Responses to a Cholesterol-Lowering Diet in 50 Men With Moderate Hypercholesterolemia
Denke and Grundy
Arch Intern Med 1994;154:317-325.
ABSTRACT  

The Efficacy of Intensive Dietary Therapy Alone or Combined with Lovastatin in Outpatients with Hypercholesterolemia
Hunninghake et al.
NEJM 1993;328:1213-1219.
ABSTRACT | FULL TEXT  

LOVASTATIN AND HIGH-FAT VERSUS LOW-FAT DIETS
JWatch General 1991;1991:2-2.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.